2-(4-tert-butylbenzoylamino)-5-amino-N-(4-methoxyphenyl)benzamide | 219491-73-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-tert-butylbenzoylamino)-5-amino-N-(4-methoxyphenyl)benzamide
• 英文别名: 5-amino-2-[(4-tert-butylbenzoyl)amino]-N-(4-methoxyphenyl)benzamide
• CAS: 219491-73-3
• 化学式: C₂₅H₂₇N₃O₃
• 分子量: 417.508
• InChiKey: ZUVRNEXUNNBKAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙酰氯 、 2-(4-tert-butylbenzoylamino)-5-amino-N-(4-methoxyphenyl)benzamide 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到5-acetamido-2-[(4-tert-butylbenzoyl)amino]-N-(4-methoxyphenyl)benzamide
  参考文献：
  名称：

  N²-Aroylanthranilamide Inhibitors of Human Factor Xa

  摘要：

  Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K-ass = 0.81 x 10(6) L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N-2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only small planar substituents could be accommodated in the A-ring for binding to the S1 site of hfXa. Bulky groups such as 4-isopropyl, 4-tert-butyl, and C-dimethylamino were favored in the B-ring to interact with the S4 site of hfXa. The central (C) ring containing a 5-methanesulfonamido group yielded greater activity than carbamoyl groups. Combining the beneficial features from the B- and C-ring SAR, compound 55 represents the most potent hfXa inhibitor in the N-2-aroylanthranilamide 4 series with hfXa K-ass = 58 x 10(6) L/mol (K-i = 11.5 nM).

  DOI：

  10.1021/jm990327e
• 作为产物：
  描述：

  对叔丁基苯甲酰氯 在 10 percent Pd/C 吡啶 、 氢气 作用下， 以 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 75.0~80.0 ℃ 、101.33 kPa 条件下， 反应 8.5h， 生成 2-(4-tert-butylbenzoylamino)-5-amino-N-(4-methoxyphenyl)benzamide
  参考文献：
  名称：

  N²-Aroylanthranilamide Inhibitors of Human Factor Xa

  摘要：

  Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K-ass = 0.81 x 10(6) L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N-2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only small planar substituents could be accommodated in the A-ring for binding to the S1 site of hfXa. Bulky groups such as 4-isopropyl, 4-tert-butyl, and C-dimethylamino were favored in the B-ring to interact with the S4 site of hfXa. The central (C) ring containing a 5-methanesulfonamido group yielded greater activity than carbamoyl groups. Combining the beneficial features from the B- and C-ring SAR, compound 55 represents the most potent hfXa inhibitor in the N-2-aroylanthranilamide 4 series with hfXa K-ass = 58 x 10(6) L/mol (K-i = 11.5 nM).

  DOI：

  10.1021/jm990327e

文献信息

• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US06313122B1

  公开（公告）日：2001-11-06

  This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  这项申请涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。
• [EN] ANTITHROMBOTIC AGENTS<br/>[FR] AGENTS ANTITHROMBOTIQUES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1999000121A1

  公开（公告）日：1999-01-07

  (EN) This application relates to a compound of formula (I) (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.(FR) Cette invention traite d'un composé de la formule (I), telle que définie dans le descriptif, (ou bien d'un promédicament de ce composé ou bien d'un sel pharmaceutiquement acceptable de ce composé ou d'un promédicament de ce composé), de compositions pharmaceutiques contenant ce composé, de l'utilisation de ce composé en tant qu'inhibiteur du facteur Xa, d'un procédé permettant de préparer ce composé et d'intermédiaires utilisés pour produire ledit composé.

  该申请涉及公式（I）的化合物（或其前药或化合物或前药的药学上可接受的盐），其药物组成，以及其作为因子Xa的抑制剂的用途，以及其制备过程和中间体。
• SYNTHESIS OF HYDROGEN PEROXIDE
  申请人：——

  公开号：US20010007045A1

  公开（公告）日：2001-07-05

  A method for synthesizing hydrogen peroxide comprises the steps of: synthesizing an analog of anthraquinone that is miscible or soluble in carbon dioxide; reacting the analog of anthraquinone with hydrogen in carbon dioxide to produce a corresponding analog of tetrahydroquinone; and reacting the analog of tetrahydroquinone with oxygen to produce the hydrogen peroxide and regenerate the analog of anthraquinone. A chemical compound having the formula: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently, the same or different, H, R C , or R S R C , wherein R S is a spacer group and R C is a fluoroalkyl group, a fluoroether group, a silicone group, an alkylene oxide group, a fluorinated acrylate group, or a phosphazine group, and wherein at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is not H.

  一种合成过氧化氢的方法包括以下步骤：合成可混溶或溶于二氧化碳的蒽醌类似物；使蒽醌类似物与二氧化碳中的氢反应，生成相应的四氢醌类似物；使四氢醌类似物与氧气反应，生成过氧化氢并再生蒽醌类似物。具有以下化学式的化合物 1 其中 R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 和 R 8 分别是相同或不同的 H、R C 或 R S R C 其中 R S 是间隔基团，R C 是氟烷基、氟醚基、硅酮基、环氧亚烷基、氟化丙烯酸酯基或磷嗪基，其中 R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 和 R 8 不是 H。
• Synthesis of hydrogen peroxide
  申请人：——

  公开号：US20020110516A1

  公开（公告）日：2002-08-15

  A method for synthesizing hydrogen peroxide comprises the steps of: synthesizing an analog of anthraquinone that is miscible or soluble in carbon dioxide; reacting the analog of anthraquinone with hydrogen in carbon dioxide to produce a corresponding analog of tetrahydroquinone; and reacting the analog of tetrahydroquinone with oxygen to produce the hydrogen peroxide and regenerate the analog of anthraquinone. A chemical compound having the formula: 1 Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently, the same or different, H, R C , or R S R C , wherein R S is a spacer group and R C is a fluoroalkyl group, a fluoroether group, a silicone group, an alkylene oxide group, a fluorinated acrylate group, or a phosphazine group, and wherein at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is not H.

  一种合成过氧化氢的方法包括以下步骤：合成可混溶或溶于二氧化碳的蒽醌类似物；使蒽醌类似物与二氧化碳中的氢反应，生成相应的四氢醌类似物；使四氢醌类似物与氧气反应，生成过氧化氢并再生蒽醌类似物。具有以下化学式的化合物 1 其中 R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 和 R 8 分别是相同或不同的 H、R C 或 R S R C 其中 R S 是间隔基团，R C 是氟烷基、氟醚基、硅酮基、环氧亚烷基、氟化丙烯酸酯基或磷嗪基，其中 R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 和 R 8 不是 H。
• ANTITHROMBOTIC AGENTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1014962A1

  公开（公告）日：2000-07-05